| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
NSC 15364 targets the voltage-dependent anion channel 1 (VDAC1), a mitochondrial membrane protein. VDAC1 oligomerization is a key step in the mitochondrial pathway of apoptosis, leading to the release of cytochrome c and other apoptotic factors. By preventing VDAC1 oligomerization, NSC 15364 inhibits this apoptotic pathway.
|
|---|---|
| ln Vitro |
One of the main targets of medications meant to control cells is the oligomerization of mitochondrial membrane protein potential channel 1 (VDAC1) [1].
In vitro, NSC 15364 is an inhibitor of VDAC1 oligomerization and apoptosis. It can be used for screening of ALR inhibitors by detection of hydrogen peroxide production. Its mechanism of action is confirmed by its ability to prevent the formation of VDAC1 oligomers in cellular or cell-free systems. |
| ln Vivo |
In vivo, NSC 15364's ability to inhibit apoptosis makes it a valuable tool for studying diseases characterized by excessive apoptosis. By preventing VDAC1 oligomerization, it could potentially protect cells from apoptotic cell death. Its in vivo efficacy would need to be confirmed in appropriate animal models.
|
| Enzyme Assay |
Non-cellular assays for NSC 15364 involve measuring its ability to prevent VDAC1 oligomerization. This can be done using purified VDAC1 protein and cross-linking agents, followed by SDS-PAGE and Western blot to detect oligomer formation. The compound's direct binding to VDAC1 can be assessed using surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC).
|
| Cell Assay |
In vitro cellular assays for NSC 15364 are conducted to assess its effects on apoptosis. Cells are treated with an apoptotic stimulus (e.g., staurosporine, etoposide) in the presence or absence of NSC 15364. Apoptosis is measured by assessing caspase activation, cytochrome c release, and DNA fragmentation. VDAC1 oligomerization is measured by cross-linking and Western blot.
|
| Animal Protocol |
In vivo animal experiments with NSC 15364 are conducted in models of diseases where apoptosis plays a key role, such as ischemia-reperfusion injury, neurodegeneration, or certain cancers. The compound is administered, and its effects on tissue damage, cell death, and functional recovery are assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for NSC 15364 are limited. It has a molecular weight of 242.28. It is soluble in DMSO and is typically stored as a powder at -20°C. Its half-life and bioavailability would need to be characterized for in vivo use.
|
| Toxicity/Toxicokinetics |
NSC 15364 is considered to have low toxicity based on its use as a research compound. However, comprehensive toxicological data are not extensively published. The compound is intended for research use only and is not approved for human therapeutic use.
|
| References | |
| Additional Infomation |
NSC 15364 is an inhibitor of VDAC1 oligomerization and apoptosis. It directly interacts with VDAC1 to prevent its oligomerization, thereby inhibiting mitochondrial-mediated apoptosis. It is a valuable tool for studying mitochondrial function and cell survival mechanisms.
|
| Molecular Formula |
C₁₃H₁₄N₄O
|
|---|---|
| Molecular Weight |
242.28
|
| Exact Mass |
242.116
|
| CAS # |
4550-72-5
|
| PubChem CID |
225703
|
| Appearance |
Gray to brown solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
381.4±27.0 °C at 760 mmHg
|
| Flash Point |
184.5±23.7 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.785
|
| LogP |
-0.5
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
18
|
| Complexity |
242
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
MAPWYRGGJSHAAU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H14N4O/c14-9-1-5-11(6-2-9)16-13(18)17-12-7-3-10(15)4-8-12/h1-8H,14-15H2,(H2,16,17,18)
|
| Chemical Name |
1,3-bis(4-aminophenyl)urea
|
| Synonyms |
NSC 15364 NSC 15364
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~206.37 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (10.32 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (8.59 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.1275 mL | 20.6373 mL | 41.2746 mL | |
| 5 mM | 0.8255 mL | 4.1275 mL | 8.2549 mL | |
| 10 mM | 0.4127 mL | 2.0637 mL | 4.1275 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
